IGF2 signaling and regulation in cancer

Cytokine and Growth Factor Reviews

Volumn 26, Issue 3, 2015, Pages 371-377

  Brouwer Visser, Jurriaan ^a   Huang, Gloria S ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Cancer; Chemoresistance; IGF2

Indexed keywords

MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 57;

CANCER RESISTANCE; DNA METHYLATION; DRUG TARGETING; GENE AMPLIFICATION; GENE CONTROL; GENE STRUCTURE; GENOME IMPRINTING; HUMAN; IGF2 GENE; MOLECULAR PATHOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMISTRY; DRUG RESISTANCE; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; INSULIN-LIKE GROWTH FACTOR II; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84929654387     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.01.002     Document Type: Short Survey

References (79)

1. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 2004, 26(December (12)):1351-1362.
2. Livingstone C. IGF2 and cancer. Endocr Relat Cancer 2013, 20(December (6)):R321-R339.
3. Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75(October (1)):73-82.
4. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75(October (1)):59-72.
5. Holthuizen P.E. The many levels of control of IGF-II expression. Insulin-like growth factors 2003, 91-103. Eurekah.com and Kluwer Academic/Plenum Publishers.
6. Harris L.K., Westwood M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors 2012, 30(February (1)):1-12.
7. Weksberg R., Smith A.C., Squire J., Sadowski P. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003, 12 Spec No. 1(April (Suppl. 1)):R61-R68.
8. Rancourt R.C., Harris H.R., Barault L., Michels K.B. The prevalence of loss of imprinting of H19 and IGF2 at birth. FASEB J 2013, 27(August (8)):3335-3343.
9. Manara M.C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P.L., et al. Preclinical in vivo study of new insulin-like growth factor-I receptor - specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007, 13(February (4)):1322-1330.
10. Singer C.F., Mogg M., Koestler W., Pacher M., Marton E., Kubista E., et al. Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res 2004, 10(June (12 Pt 1)):4003-4009.
11. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Risch H.A., Puopolo M., et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006, 12(February (4)):1208-1214.
12. Chao W., D'Amore P.A. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008, 19(April (2)):111-120.
13. Ratajczak M.Z. Igf2-H19, an imprinted tandem gene, is an important regulator of embryonic development, a guardian of proliferation of adult pluripotent stem cells, a regulator of longevity, and a passkey to cancerogenesis. Folia Histochem Cytobiol 2012, 50(2):171-179.
14. Mineo R., Fichera E., Liang S.-J., Fujita-Yamaguchi Y. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. Biochem Biophys Res Commun 2000, 268(February (3)):886-892.
15. Li J., Neumann I., Volkmer I., Staege M.S. Down-regulation of achaete-scute complex homolog 1 (ASCL1) in neuroblastoma cells induces up-regulation of insulin-like growth factor 2 (IGF2). Mol Biol Rep 2011, 38(March (3)):1515-1521.
16. Lui J.C., Baron J. Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3. Proc Natl Acad Sci USA 2013, 110(April (15)):6181-6186.
17. Monk D. Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet 2006, 15(April (8)):1259-1269.
18. Pearce C.L., Doherty J.A., Van Den Berg D.J., Moysich K., Hsu C., Cushing-Haugen K.L., et al. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet 2011, 20(June (11)):2263-2272.
19. Kanatsuna N., Taneera J., Vaziri-Sani F., Wierup N., Larsson H.E., Delli A., et al. Autoimmunity against INS-IGF2 protein expressed in human pancreatic islets. J Biol Chem 2013, 288(October (40)):29013-29023.
20. Greenall S.A., Bentley J.D., Pearce L.A., Scoble J.A., Sparrow L.G., Bartone N.A., et al. Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer. J Biol Chem 2013, 288(January (1)):59-68.
21. Huang Y.-F., Cheng W.-F., Wu Y.-P., Cheng Y.-M., Hsu K.-F., Chou C.-Y. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer 2014, 21(April (2)):217-229.
22. Rikhof B., van der Graaf W.T.A., Suurmeijer A.J.H., van Doorn J., Meersma G.J., Groenen P.J.T.A., et al. Big-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors. Am J Pathol 2012, 181(July (1)):303-312.
23. Hizuka N., Fukuda I., Takano K., Okubo Y., Asakawa-Yasumoto K., Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J 1998, 45(April (Suppl.)):S61-S65.
24. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009, 30(October (6)):586-623.
25. Bruchim I., Sarfstein R., Werner H. The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches. Front Endocrinol 2014, 5:76.
26. Cui H., Cruz-Correa M., Giardiello F.M., Hutcheon D.F., Kafonek D.R., Brandenburg S., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299(March (5613)):1753-1755.
27. Dai Y., Wang Z., Li J., Gu X., Zheng M., Zhou J., et al. Imprinting status of IGF2 in cord blood cells of Han Chinese newborns. Int J Mol Sci 2007, 8:273-283.
28. Ekstrom T.J., Cui H., Li X., Ohlsson R. Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development 1995, 121(February (2)):309-316.
29. Yang B., Wagner J., Damaschke N., Yao T., Wuerzberger-Davis S.M., Lee M.-H. A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLOS ONE 2014, 9(2):e88052.
30. Balch C., Nephew K.P. Epigenetic targeting therapies to overcome chemotherapy resistance. Adv Exp Med Biol 2013, 754:285-311.
31. Murphy S.K., Huang Z., Wen Y., Spillman M.A., Whitaker R.S., Simel L.R., et al. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006, 4(April (4)):283-292.
32. Qian B., Katsaros D., Lu L., Canuto E.M., Benedetto C., Beeghly-Fadiel A., et al. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncol Rep 2011, 25(January (1)):203-213.
33. Huang Z., Murphy S.K. Increased intragenic IGF2 methylation is associated with repression of insulator activity and elevated expression in serous ovarian carcinoma. Front Oncol 2013, 3:131.
34. Cancer Genome Atlas Network, Getz G. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487(July (7407)):330-337.
35. Liu M., Roth A., Yu M., Morris R., Bersani F., Rivera M.N., et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev 2013, 27(December (23)):2543-2548.
36. Li X., Nadauld L., Ootani A., Corney D.C., Pai R.K., Gevaert O., et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 2014, 20(July (7)):769-777.
37. Gebeshuber C.A., Martinez J. miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene 2013, 32(July (27)):3306-3310.
38. Gao W., Gu Y., Li Z., Cai H., Peng Q., Tu M., et al. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene 2014, (April).
39. Monnier P., Martinet C., Pontis J., Stancheva I., Ait-Si-Ali S., Dandolo L. H19 lncRNA controls gene expression of the imprinted gene network by recruiting MBD1. Proc Natl Acad Sci USA 2013, 110(December (51)):20693-20698.
40. Tada Y., Yamaguchi Y., Kinjo T., Song X., Akagi T., Takamura H., et al. The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells. Oncogene 2014, (January).
41. Li B., Tsao S.W., Chan K.W., Ludwig D.L., Novosyadlyy R., Li Y.Y., et al. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance - implications for IGF-II and IGF-IR-targeted therapy. Clin Cancer Res 2014, 20(May (10)):2651-2662.
42. Haley V.L., Barnes D.J., Sandovici I., Constancia M., Graham C.F., Pezzella F., et al. Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes. EMBO Mol Med 2012, 4(August (8)):705-718.
43. Ludwig T., Eggenschwiler J., Fisher P., D'Ercole A.J., Davenport M.L., Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 1996, 177(August (2)):517-535.
44. Maeng Y.-S., Choi H.-J., Kwon J.-Y., Park Y.-W., Choi K.-S., Min J.-K., et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCbeta2 axis. Blood 2009, 113(January (1)):233-243.
45. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., Nielsen F.C. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999, 19(February (2)):1262-1270.
46. Lederer M., Bley N., Schleifer C., Hüttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cell Biol 2014, 29(December):3-12.
47. Samanta S., Pursell B., Mercurio A.M. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem 2013, 288(May (18)):12569-12573.
48. Liao B., Hu Y., Herrick D.J., Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005, 280(May (18)):18517-18524.
49. Suvasini R., Shruti B., Shinde S.V., Friedmann-Morvinski D., Nawaz Z., Prasanna K.V., et al. Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem 2011, 286(July (29)):25882-25890.
50. Dai N., Rapley J., Angel M., Yanik M.F., Blower M.D., Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev 2011, 25(June (11)):1159-1172.
51. Dai N., Christiansen J., Nielsen F.C., Avruch J. mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes Dev 2013, 27(February (3)):301-312.
52. Liao B., Hu Y., Brewer G. RNA-binding protein IMP-3 promotes cell survival via IGF-II signaling after ionizing radiation. J Biol Chem 2011, 286(July (36)). 10.1074/jbc.M111.263913.
53. Huang G.S., Brouwer-Visser J., Ramirez M.J., Kim C.H., Hebert T.M., Lin J., et al. Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010, 16(June (11)):2999-3010.
54. Brouwer-Visser J., Lee J., McCullagh K., Cossio M.J., Wang Y., Huang G.S. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. PLOS ONE 2014, 9(June (6)):e100165.
55. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(June (7353)):609-615.
56. Ogawa T., Ogawa K., Shiga K., Furukawa T., Nagase H., Hashimoto S., et al. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2010, 267(October (10)):1599-1606.
57. Shimizu T., Sugihara E., Yamaguchi-Iwai S., Tamaki S., Koyama Y., Kamel W., et al. IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. Cancer Res 2014, 74(November (22)):6531-6541.
58. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012, 104(July (13)):975-981.
59. Brana I., Berger R., Golan T., Haluska P., Edenfield J., Fiorica J., et al. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer 2014, (October).
60. Shin D.H., Lee H.-J., Min H.-Y., Choi S.P., Lee M.-S., Lee J.W., et al. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway. J Natl Cancer Inst 2013, 105(October (20)):1558-1570.
61. Yee D. A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 2014, (October).
62. Beltran P.J., Calzone F.J., Mitchell P., Chung Y.-A., Cajulis E., Moody G., et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res 2014, 20(June (11)):2947-2958.
63. Puzanov I., Lindsay C.R., Goff L.W., Sosman J.A., Gilbert J., Berlin J., et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors in patients with advanced solid tumors. Clin Cancer Res 2014, (September).
64. Jones R.L., Kim E.S., Nava-Parada P., Alam S., Johnson F.M., Stephens A.W., et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res 2014, (September).
65. Gao J., Chesebrough J.W., Cartlidge S.A., Ricketts S.-A., Incognito L., Veldman-Jones M., et al. Dual IGF-I/II - neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011, 71(February (3)):1029-1040.
66. Dransfield D.T., Cohen E.H., Chang Q., Sparrow L.G., Bentley J.D., Dolezal O., et al. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 2010, 9(June (6)):1809-1819.
67. Fukuda I., Hizuka N., Ishikawa Y., Yasumoto K., Murakami Y., Sata A., et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res 2006, 16(August (4)):211-216.
68. Amit D., Tamir S., Hochberg A. Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences. Int J Clin Exp Med 2013, 6(2):110-118.
69. Fung E.C., Crook M.A. Doege-Potter syndrome and 'big-IGF2': a rare cause of hypoglycaemia. Ann Clin Biochem 2011, 48:95-96. 10.1258/acb.2011.011020.
70. Soroceanu L., Kharbanda S., Chen R., Soriano R.H., Aldape K., Misra A., et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA 2007, 104:3466-3471. 10.1073/pnas.0611271104.
71. Tian F., Yourek G., Shi X., Yang Y. The development of Wilms tumor: from WT1 and microRNA to animal models. Biochim Biophys Acta 2014, 1846:180-187. 10.1016/j.bbcan.2014.07.003.
72. Maschietto M., Charlton J., Perotti D., Radice P., Geller J.I., Pritchard-Jones K., et al. The IGF signalling pathway in Wilms tumours-a report from the ENCCA Renal Tumours Biology-driven drug development workshop. Oncotarget 2014, 5:8014-8026.
73. Zhan S., Shapiro D.N., Helman L.J. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995, 11:2503-2507.
74. Shetty P.J., Movva S., Pasupuleti N., Vedicherlla B., Vattam K.K., Venkatasubramanian S., et al. Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. J Cancer Res Clin Oncol 2011, 137:339-345. 10.1007/s00432-010-0890-z.
75. Murata A., Baba Y., Watanabe M., Shigaki H., Miyake K., Ishimoto T., et al. IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 2014, 21:1166-1174. 10.1245/s10434-013-3414-7.
76. Danielsen S.A., Eide P.W., Nesbakken A., Guren T., Leithe E., Lothe R.A. Portrait of the PI3K/AKT-pathway in colorectal cancer. Biochim Biophys Acta 2014, 10.1016/j.bbcan.2014.09.008.
77. Li Y., Meng G., Huang L., Guo Q.-N. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. Hum Pathol 2009, 40:1441-1447. 10.1016/j.humpath.2009.03.003.
78. Pivonello C., De Martino M.C., Negri M., Cuomo G., Cariati F., Izzo F., et al. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agents Cancer 2014, 9:27. 10.1186/1750-9378-9-27.
79. Matsumoto K., Lucarelli E., Minniti C., Gaetano C., Thiele C.J. Signals transduced via insulin-like growth factor I receptor (IGF(R)) mediate resistance to retinoic acid-induced cell growth arrest in a human neuroblastoma cell line. Cell Death Differ 1994, 1:49-58.